Tag: Hatch-Waxman Act
Discover why generic drugs cost 80% less than brand names. This guide explains bioequivalence, the Hatch-Waxman Act, and real 2025-2026 pricing data to help you save money safely.
Tentative approval lets generic drug makers get FDA clearance before patents expire, but litigation and timing determine when they can actually sell their products. Here’s how it works-and why missing deadlines costs millions.
An ANDA is the FDA's pathway for approving generic drugs without repeating costly clinical trials. It saves patients billions annually by ensuring safe, effective copies of brand-name medications enter the market quickly.